Abstract: FR-PO841
Safety and Tolerability of Tixagevimab/Cilgavimab for Pre-Exposure Prophylaxis of COVID-19 in Kidney Transplant Recipients
Session Information
- Transplantation: Clinical - Outcomes
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2002 Transplantation: Clinical
Authors
- Salinas, Thalia, Weill Cornell Medicine, New York, New York, United States
- Stryjniak, Gabriel J., Weill Cornell Medicine, New York, New York, United States
- Lee, John Richard, Weill Cornell Medicine, New York, New York, United States
- Sawinski, Deirdre L., Weill Cornell Medicine, New York, New York, United States
- Muthukumar, Thangamani, Weill Cornell Medicine, New York, New York, United States
- Dadhania, Darshana M., Weill Cornell Medicine, New York, New York, United States
Background
Kidney transplant recipients (KTR) remain at risk for severe COVID-19 because of emerging SARS-CoV-2 variants and impaired antibody response to COVID-19 vaccines. There is an urgent need for effective vaccination and pre-exposure prophylaxis. In December 2021, the FDA issued an emergency use authorization of tixagevimab/cilgavimab for pre-exposure prophylaxis of COVID-19 in moderately-severely immunocompromised individuals. In PROVENT, tixagevimab/cilgavimab resulted in 83% relative risk reduction in incidence of symptomatic COVID-19, but only 3% of subjects received immunosuppressive medications and <1% had immunosuppressive disease. We report safety and tolerability of tixagevimab/cilgavimab in KTR at our center.
Methods
40 doses initially allocated to KTR. We designed an online questionnaire to assess therapy tolerability. 28/38 KTR who received therapy responded.
Results
Patient characteristics of 38 KTR who received tixagevimab/cilgavimab are listed (Table 1a). Negative Anti-S antibody documented in 54.1% patients, with 17(85%) testing negative after three vaccines. 28 KTR completed the survey and authorized use of their deidentified data. Most patients, 81.5%, reported tolerating tixagevimab/cilgavimab “Very Well” (Table 1b). The most common symptom was fatigue, moderate in 25% and mild in 29%. Other symptoms were less frequent, <15%.
Conclusion
Tixagevimab/cilgavimab was generally “very well” tolerated. Additional data substantiating safety and tolerability of tixagevimab/cilgavimab over a longer observation period and with more study participants should help increase confidence in a pre-exposure prophylaxis strategy and offer a safety net for kidney transplant recipients and others at risk for severe COVID-19.